Navigation Links
Inverness Completes Acquisition of Cholestech

WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading manufacturer and marketer of rapid diagnostic products for the consumer and professional markets, announced today the successful completion of its acquisition of Cholestech Corporation (Nasdaq: CTEC). Inverness completed the acquisition through the merger of a wholly owned subsidiary with and into Cholestech, after Cholestech's shareholders approved the deal at a shareholder's meeting today. Cholestech is a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and inflammatory disorders.

"The acquisition of Cholestech together with our recent and pending acquisitions, provides Inverness with the unique ability to assess cardiac risk, diagnose cardiac conditions and potentially monitor the condition and response to therapy of cardiac patients. The Cholestech LDX System is one of the most established and respected monitoring platforms available to physicians and patients and we believe that this added access to physicians' office laboratories will provide broad benefits for many Inverness and Biosite products," stated Ron Zwanziger, Chairman, President and Chief Executive Officer of Inverness. "We welcome Cholestech and its associates to the Inverness Medical family."

As a result of the merger, Cholestech stockholders received .43642 shares of Inverness common stock for each Cholestech share, resulting in an aggregate issuance of approximately 6,801,946 shares of Inverness common stock. Additionally, each option to purchase shares of Cholestech common stock outstanding prior to the completion of the acquisition has been converted into a right to acquire Inverness shares, at the same exchange ratio of .43642. Cholestech shares will cease trading at the close of business on September 12, 2007 and will be delisted from the Nasdaq.

About Inverness:

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For additional information on Inverness Medical Innovations, please visit our website at

This press release may contain forward-looking statements within the meaning of the federal securities laws. These statements reflect Inverness' current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors, including, without limitation, the demand for Cholestech's products, Inverness' ability to integrate Cholestech's business with its existing businesses and to recognize the anticipated benefits of the acquisition, including synergies and accretion, of the transaction; the risks and uncertainties described in Inverness' annual report on Form 10-K/A for the period ended December 31, 2006, and other factors identified from time to time in its periodic filings with the Securities and Exchange Commission. Inverness undertakes no obligation to update any forward- looking statements contained herein.

SOURCE Inverness Medical Innovations, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. iGATE Completes Phase I Testing Of Meningitis Vaccine
2. Delhi Hospital Completes 100 Liver Transplants
3. Roche Completes Acquisition of BioVeris
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
6. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
7. Smoking Increases Risk of HIV Acquisition
8. Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology
Post Your Comments:
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
Breaking Medicine Technology: